3/25
09:04 am
imux
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
3/20
02:06 am
imux
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/12
11:05 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/3
06:30 am
imux
Immunic to Participate in Scientific and Investor Conferences in March
Low
Report
Immunic to Participate in Scientific and Investor Conferences in March
2/26
08:36 am
imux
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
2/26
06:55 am
imux
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis [Yahoo! Finance]
Low
Report
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis [Yahoo! Finance]
2/26
06:30 am
imux
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Low
Report
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
2/22
09:59 pm
imux
Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week [Yahoo! Finance]
Medium
Report
Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week [Yahoo! Finance]
2/22
02:15 am
imux
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/21
08:13 am
imux
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
2/20
05:46 pm
imux
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
2/20
08:03 am
imux
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing [Yahoo! Finance]
Medium
Report
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing [Yahoo! Finance]
2/20
07:30 am
imux
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Medium
Report
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
2/10
10:33 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/4
06:30 am
imux
Immunic to Participate in Investor and Scientific Conferences in February
Low
Report
Immunic to Participate in Investor and Scientific Conferences in February
1/31
11:07 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
1/7
08:20 am
imux
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
1/7
06:59 am
imux
Immunic Highlights 2024 Accomplishments and Upcoming Milestones [Yahoo! Finance]
Neutral
Report
Immunic Highlights 2024 Accomplishments and Upcoming Milestones [Yahoo! Finance]
1/7
06:30 am
imux
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Neutral
Report
Immunic Highlights 2024 Accomplishments and Upcoming Milestones